



# **Tuberculosis Country Profile 2021 Nepal**

*Source: Global tuberculosis report 2021. Geneva: World Health Organization*

*Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.*

# Tuberculosis profile: Nepal

Population 2020: 29 million

## Estimates of TB burden\*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	69 000 (41 000-104 000)	235 (139-356)
HIV-positive TB incidence	1 400 (400-2 900)	4.6 (1.4-9.9)
HIV-negative TB mortality	16 000 (7 300-28 000)	55 (25-96)
HIV-positive TB mortality	210 (98-380)	0.74 (0.34-1.3)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2020	40% (26-67)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	25% (9-46)

## TB case notifications, 2020

Total new and relapse	27 282
- % tested with rapid diagnostics at time of diagnosis	28%
- % with known HIV status	52%
- % pulmonary	68%
- % bacteriologically confirmed <sup>^</sup>	80%
- % children aged 0-14 years	6%
- % women (aged ≥15 years)	34%
- % men (aged ≥15 years)	60%
Total cases notified	27 745

## TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	123	0.87%
- on antiretroviral therapy	113	92%

## Drug-resistant TB care\*\*, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>^</sup>	60%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>^</sup>	96%
Laboratory-confirmed cases - MDR/RR-TB <sup>^^</sup>	593
Patients started on treatment - MDR/RR-TB <sup>^^</sup>	384
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>^^</sup>	84
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>^^</sup>	76
MDR/RR-TB cases tested for resistance to any fluoroquinolone	

## Treatment success rate and cohort size

	Success	Cohort
New cases registered in 2019	89%	27 484
Previously treated cases registered in 2019	90%	2 980
HIV-positive TB cases registered in 2019	69%	29
MDR/RR-TB cases started on second-line treatment in 2018	75%	328
XDR-TB cases started on second-line treatment in 2018	67%	6


## TB preventive treatment, 2020

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	38% (35-42)


## TB financing

National TB budget, 2021 (US\$ millions)	24
- Funding source, domestic	30%
- Funding source, international	38%
- unfunded	32%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2020 (Number)



## Cases attributable to five risk factors, 2020 (Number)



## Total budget (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
 \*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
<sup>^</sup> Calculated for pulmonary cases only  
<sup>^^</sup> Includes cases with unknown previous TB treatment history  
<sup>^^^</sup> Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed